Alvotech

Contributing Author

Recent Articles by Alvotech

Oct-22	Alvotech Announces Changes in Global Business Development and Commercial Operations Team ALVO GlobeNewswire
Oct-22	Alvotech Announces Changes in Global Business Development and Commercial Operations Team ALVO GlobeNewswire
Oct-06	European Marketing Application for AVT23, a Proposed Biosimilar to Xolair (omalizumab), Accepted by the European Medicines Agency ALVO GlobeNewswire
Oct-06	European Marketing Application for AVT23, a Proposed Biosimilar to Xolair (omalizumab), Accepted by the European Medicines Agency ALVO GlobeNewswire
Sep-22	European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia and Xgeva ALVO GlobeNewswire
Sep-22	European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia and Xgeva ALVO GlobeNewswire
Sep-22	European Medicines Agency Recommends Marketing Approval of Gobivaz, Alvotech's Proposed Biosimilar to Simponi (golimumab) with Advanz Pharma as Commercialization Partner ALVO GlobeNewswire
Sep-22	European Medicines Agency Recommends Marketing Approval of Gobivaz, Alvotech's Proposed Biosimilar to Simponi (golimumab) with Advanz Pharma as Commercialization Partner ALVO GlobeNewswire
Sep-19	Alvotech Announces Marketing Approval in Japan of Three New Biosimilars ALVO GlobeNewswire
Sep-19	Alvotech Announces Marketing Approval in Japan of Three New Biosimilars ALVO GlobeNewswire
Sep-04	Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York ALVO GlobeNewswire
Sep-04	Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York ALVO GlobeNewswire
Aug-21	Advanz Pharma and Alvotech receive European approval for Mynzepli, Biosimilar to Eylea ALVO GlobeNewswire
Aug-21	Advanz Pharma and Alvotech receive European approval for Mynzepli, Biosimilar to Eylea ALVO GlobeNewswire
Aug-20	Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia ALVO GlobeNewswire
Aug-13	Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update ALVO GlobeNewswire
Aug-13	Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update ALVO GlobeNewswire
Aug-06	Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT ALVO GlobeNewswire
Aug-06	Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT ALVO GlobeNewswire
Jul-10	Alvotech Appoints Linda Jonsdottir as Chief Financial Officer ALVO GlobeNewswire
Jul-10	Alvotech Appoints Linda Jonsdottir as Chief Financial Officer ALVO GlobeNewswire
Jul-09	Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland ALVO GlobeNewswire
Jul-09	Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland ALVO GlobeNewswire
Jul-03	Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers ALVO GlobeNewswire
Jul-01	Granting of Stock Options and Vesting of Restricted Share Units ALVO GlobeNewswire
Jul-01	Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia (certolizumab pegol) ALVO GlobeNewswire
Jul-01	Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia (certolizumab pegol) ALVO GlobeNewswire
Jun-26	Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility ALVO GlobeNewswire
Jun-26	Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility ALVO GlobeNewswire
Jun-25	Main Results of 2025 Annual and Extraordinary General Meeting ALVO GlobeNewswire
Jun-25	Main Results of 2025 Annual and Extraordinary General Meeting ALVO GlobeNewswire
Jun-25	Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair (omalizumab) ALVO GlobeNewswire
Jun-25	Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair (omalizumab) ALVO GlobeNewswire
Jun-23	European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea (aflibercept) ALVO GlobeNewswire
Jun-23	European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea (aflibercept) ALVO GlobeNewswire
Jun-11	Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors ALVO GlobeNewswire
Jun-11	Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors ALVO GlobeNewswire
Jun-06	Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami ALVO GlobeNewswire
Jun-06	Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami ALVO GlobeNewswire
Jun-05	Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda (pembrolizumab) ALVO GlobeNewswire
Jun-05	Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda (pembrolizumab) ALVO GlobeNewswire
Jun-04	Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million ALVO GlobeNewswire
Jun-04	Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million ALVO GlobeNewswire
Jun-04	Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares ALVO GlobeNewswire
Jun-04	Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia ALVO GlobeNewswire
Jun-02	Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY ALVO GlobeNewswire
Jun-02	Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY ALVO GlobeNewswire
May-28	Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe ALVO GlobeNewswire
May-28	Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe ALVO GlobeNewswire
May-26	Alvotech Annual General Meeting to be held June 25, 2025 ALVO GlobeNewswire
May-23	Transactions of Managers and Closely Associated Persons ALVO GlobeNewswire
May-19	Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm ALVO GlobeNewswire
May-19	Trading in Alvotech's Shares on Nasdaq Stockholm Commences Today ALVO GlobeNewswire
May-16	Alvotech Announces the Outcome of the Offering in Connection with the Company's Listing on Nasdaq Stockholm ALVO GlobeNewswire
May-16	Transactions of Managers and Closely Associated Persons ALVO GlobeNewswire
May-13	Transactions of Managers and Closely Associated Persons ALVO GlobeNewswire
May-09	Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada ALVO GlobeNewswire
May-09	Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada ALVO GlobeNewswire
May-09	Transactions of Managers and Closely Associated Persons ALVO GlobeNewswire
May-08	Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm ALVO GlobeNewswire
May-07	Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update ALVO GlobeNewswire
May-07	Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update ALVO GlobeNewswire
May-07	Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech's Product Revenues in 2025 ALVO GlobeNewswire
May-07	Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech's Product Revenues in 2025 ALVO GlobeNewswire
May-05	Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI (ustekinumab-aekn) with Stelara (ustekinumab) ALVO GlobeNewswire
May-05	Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI (ustekinumab-aekn) with Stelara (ustekinumab) ALVO GlobeNewswire
May-02	Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET) ALVO GlobeNewswire
May-02	Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT ALVO GlobeNewswire

Alvotech

Recent Articles by Alvotech

Upgrade your FINVIZ experience